{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:41:22Z","timestamp":1792424482174,"version":"4.5.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21wm0425015"],"award-info":[{"award-number":["JP21wm0425015"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24wm0625001"],"award-info":[{"award-number":["JP24wm0625001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["24zf0127012"],"award-info":[{"award-number":["24zf0127012"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["JPMJMS2024"],"award-info":[{"award-number":["JPMJMS2024"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI radiopharm. chem."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      <jats:sup>18<\/jats:sup>\n                      F-Labeled (\n                      <jats:italic>E<\/jats:italic>\n                      )-1-fluoro-3-((2-(4-(5-(methylamino)pyrazin-2-yl)but-1-en-3-yn-1-yl)benzo[\n                      <jats:italic>d<\/jats:italic>\n                      ]thiazol-6-yl)oxy)propan-2-ol ([\n                      <jats:sup>18<\/jats:sup>\n                      F]SPAL-T-06) and (\n                      <jats:italic>E<\/jats:italic>\n                      )-1-fluoro-3-((2-(4-(6-(methylamino)pyridine-3-yl)but-1-en-3-yn-1-yl)benzo[d]thiazol-6-yl)oxy)propan-2-ol ([\n                      <jats:sup>18<\/jats:sup>\n                      F]C05-05) are positron emission tomography (PET) imaging agents for \u03b1-synuclein pathologies. Recently, we demonstrated the utility of PET imaging with [\n                      <jats:sup>18<\/jats:sup>\n                      F]SPAL-T-06 for \u03b1-synuclein pathologies in patients with multiple system atrophy and with [\n                      <jats:sup>18<\/jats:sup>\n                      F]C05-05 for \u03b1-synuclein pathologies in Parkinson\u2019s disease and related disorders. In this study, to establish [\n                      <jats:sup>18<\/jats:sup>\n                      F]SPAL-T-06 and [\n                      <jats:sup>18<\/jats:sup>\n                      F]C05-05 as PET radiopharmaceuticals for clinical investigations, we developed routine radiosynthetic procedures using an\n                      <jats:sup>18<\/jats:sup>\n                      F-labeling synthesizer and performed quality control (QC) testing of these two PET radiopharmaceuticals.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>18<\/jats:sup>\n                      F]SPAL-T-06 and [\n                      <jats:sup>18<\/jats:sup>\n                      F]C05-05 were synthesized by direct\n                      <jats:sup>18<\/jats:sup>\n                      F-fluorination of their respective tetrahydropyranyl-protected tosylated precursors, followed by deprotection, using an\n                      <jats:sup>18<\/jats:sup>\n                      F-labeling synthesizer. The non-decay-corrected radiochemical yields of [\n                      <jats:sup>18<\/jats:sup>\n                      F]SPAL-T-06 and [\n                      <jats:sup>18<\/jats:sup>\n                      F]C05-05 from\n                      <jats:sup>18<\/jats:sup>\n                      F\n                      <jats:sup>\u2212<\/jats:sup>\n                      at the end of synthesis (EOS) were 11\u2009\u00b1\u20094.6% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200919) and 20\u2009\u00b1\u20096.8% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200937), respectively. The radiochemical purities of both PET radiopharmaceuticals exceeded 99%. The molar activities of each PET radiopharmaceutical at EOS exceeded 68\u00a0GBq\/\u00b5mol, and the total synthesis times were within 100\u00a0min after irradiation. In addition, [\n                      <jats:sup>18<\/jats:sup>\n                      F]SPAL-T-06 and [\n                      <jats:sup>18<\/jats:sup>\n                      F]C05-05 were efficiently separated from byproducts using a semi-preparative high-performance liquid chromatography system. All QC results for the two PET radiopharmaceuticals complied with in-house QC and quality assurance specifications. The stabilities of the two PET radiopharmaceuticals were evaluated under standard fluorescent light in a general laboratory environment and under UV-cutoff light in a natural light-shielded environment. After 10\u00a0min of exposure to the standard fluorescent light, the radiochemical purity of each tracer decreased to approximately 86%. In contrast, the radiochemical purity of each tracer exceeded 99% after 60\u00a0min under UV-cutoff light in a natural light-shielded environment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      We successfully prepared two PET radiopharmaceuticals, [\n                      <jats:sup>18<\/jats:sup>\n                      F]SPAL-T-06 and [\n                      <jats:sup>18<\/jats:sup>\n                      F]C05-05, for clinical investigation. The radiosynthesis and QC findings provide a practical basis for establishing standardized production procedures and facilitating technology transfer to other PET centers. In particularly, all post-deprotection radiosynthesis steps and QC testing for [\n                      <jats:sup>18<\/jats:sup>\n                      F]SPAL-T-06 and [\n                      <jats:sup>18<\/jats:sup>\n                      F]C05-05 should be performed under UV-cutoff light in a natural light-shielded environment to prevent photoisomerization.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41181-026-00480-w","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T04:06:58Z","timestamp":1784779618000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Radiosynthesis and quality control testing of two 18F-labeled radiopharmaceuticals for \u03b1-synuclein imaging in clinical investigations"],"prefix":"10.1186","volume":"11","author":[{"given":"Hiroki","family":"Hashimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ohkubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6786-678X","authenticated-orcid":false,"given":"Kazunori","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Fujishiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Arashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuto","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeru","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaito","family":"Tsukagoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanao","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kurihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuki","family":"Nengaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wakana","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Fujinaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Rong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"480_CR1","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1016\/j.neuron.2024.05.006","volume":"112","author":"H Endo","year":"2024","unstructured":"Endo H, Ono M, Takado Y, Matsuoka K, Takahashi M, Tagai K, et al. Imaging \u03b1-synuclein pathologies in animal models and patients with Parkinson\u2019s and related diseases. Neuron. 2024;112:2540-57.e8. https:\/\/doi.org\/10.1016\/j.neuron.2024.05.006.","journal-title":"Neuron"},{"key":"480_CR2","doi-asserted-by":"publisher","first-page":"8640","DOI":"10.1038\/s41598-025-93520-5","volume":"15","author":"R Goto","year":"2025","unstructured":"Goto R, Matsuoka K, Kimura Y, Kataoka Y, Oya M, Hirata K, et al. Human biodistribution and radiation dosimetry of two novel alpha-synuclein PET tracers, 18F-SPAL-T-06 and 18F-C05-05. Sci Rep. 2025;15:8640. https:\/\/doi.org\/10.1038\/s41598-025-93520-5.","journal-title":"Sci Rep"},{"key":"480_CR3","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.2967\/jnumed.114.139550","volume":"55","author":"H Hashimoto","year":"2014","unstructured":"Hashimoto H, Kawamura K, Igarashi N, Takei M, Fujishiro T, Aihara Y, et al. Radiosynthesis, photoisomerization, biodistribution, and metabolite analysis of 11C-PBB3 as a clinically useful PET probe for imaging of tau pathology. J Nucl Med. 2014;55:1532\u20138. https:\/\/doi.org\/10.2967\/jnumed.114.139550.","journal-title":"J Nucl Med"},{"key":"480_CR4","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41582-025-01126-2","volume":"21","author":"M Higuchi","year":"2025","unstructured":"Higuchi M, Tagai K, Takahata K, Endo H. Advances in PET imaging of protein aggregates associated with neurodegenerative disease. Nat Rev Neurol. 2025;21:506\u201322. https:\/\/doi.org\/10.1038\/s41582-025-01126-2.","journal-title":"Nat Rev Neurol"},{"key":"480_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/jlcr.3890","volume":"64","author":"K Kawamura","year":"2021","unstructured":"Kawamura K, Hashimoto H, Furutsuka K, Ohkubo T, Fujishiro T, Togashi T, et al. Radiosynthesis and quality control testing of the tau imaging positron emission tomography tracer [18F]PM-PBB3 for clinical applications. J Labelled Compd Radiopharm. 2021;64:109\u201319. https:\/\/doi.org\/10.1002\/jlcr.3890.","journal-title":"J Labelled Compd Radiopharm"},{"key":"480_CR6","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.neuron.2013.07.037","volume":"79","author":"M Maruyama","year":"2013","unstructured":"Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013;79:1094\u2013108. https:\/\/doi.org\/10.1016\/j.neuron.2013.07.037.","journal-title":"Neuron"},{"key":"480_CR7","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1002\/mds.29186","volume":"37","author":"K Matsuoka","year":"2022","unstructured":"Matsuoka K, Ono M, Takado Y, Hirata K, Endo H, Ohfusa T, et al. High-contrast imaging of \u03b1-synuclein pathologies in living patients with multiple system atrophy. Mov Disord. 2022;37:2159\u201361. https:\/\/doi.org\/10.1002\/mds.29186.","journal-title":"Mov Disord"},{"key":"480_CR8","doi-asserted-by":"publisher","first-page":"147131","DOI":"10.1016\/j.brainres.2020.147131","volume":"1749","author":"P Miranda-Azpiazu","year":"2020","unstructured":"Miranda-Azpiazu P, Svedberg M, Higuchi M, Ono M, Jia Z, Sunnemark D, et al. Identification and in vitro characterization of C05-01, a PBB3 derivative with improved affinity for alpha-synuclein. Brain Res. 2020;1749:147131. https:\/\/doi.org\/10.1016\/j.brainres.2020.147131.","journal-title":"Brain Res"},{"key":"480_CR9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuron.2020.09.042","volume":"109","author":"K Tagai","year":"2021","unstructured":"Tagai K, Ono M, Kubota M, Kitamura S, Takahata K, Seki C, et al. High-contrast in vivo imaging of tau pathologies in Alzheimer\u2019s and non-Alzheimer\u2019s disease tauopathies. Neuron. 2021;109:42\u201358. https:\/\/doi.org\/10.1016\/j.neuron.2020.09.042.","journal-title":"Neuron"},{"key":"480_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18893\/kakuigaku.tr.1503","volume":"53","author":"A Waki","year":"2016","unstructured":"Waki A, Hashimoto H, Suzuki H, Mizukawa Y, Kinoshita T, Ichihara H, et al. Development of an isolator system for PET drug compounding with sterilization and dispensing units. Kakuigaku. 2016;53:1\u20137. https:\/\/doi.org\/10.18893\/kakuigaku.tr.1503.","journal-title":"Kakuigaku"},{"key":"480_CR11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0969-8043(02)00075-1","volume":"57","author":"MR Zhang","year":"2002","unstructured":"Zhang MR, Tsuchiyama A, Haradahira T, Yoshida Y, Furutsuka K, Suzuki K. Development of an automated system for synthesizing 18F-labeled compounds using [18F]fluoroethyl bromide as a synthetic precursor. Appl Radiat Isot. 2002;57:335\u201342. https:\/\/doi.org\/10.1016\/S0969-8043(02)00075-1.","journal-title":"Appl Radiat Isot"}],"container-title":["EJNMMI Radiopharmacy and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41181-026-00480-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-026-00480-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-026-00480-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:03:20Z","timestamp":1792422200000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41181-026-00480-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["480"],"URL":"https:\/\/doi.org\/10.1186\/s41181-026-00480-w","relation":{},"ISSN":["2365-421X"],"issn-type":[{"value":"2365-421X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"7 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ming-Rong Zhang and Makoto Higuchi are inventors of patent applications related to the imaging agents described in this report, [\n                      18\n                      F]SPAL-T-06 (PCT\/JP2021\/30899) and [\n                      18\n                      F]C05-05 (2019-034997; PCT\/JP2020\/002607). All other authors declare no conflict of interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"76"}}